5 EASY FACTS ABOUT AGO TUMOR DESCRIBED

Molecular typing is based on molecular genetic screening and isn't but routinely available. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 could possibly be valuable,